Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.6K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.6K
Relaxation of Skeletal Muscles01:29

Relaxation of Skeletal Muscles

10.6K
The period of muscle contraction primarily influences the duration of stimulation at the neuromuscular junction (NMJ), the presence of free calcium ions in the sarcoplasm, and the availability of energy or ATP to support contractions.
When an action potential reaches the axon terminal, it depolarizes the membrane and opens voltage-gated sodium channels. Sodium ions enter the cell, further depolarizing the presynaptic membrane. This depolarization causes voltage-gated calcium channels to open....
10.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Mechanisms of Membrane-bending01:15

Mechanisms of Membrane-bending

3.7K
The living membranes are flexible due to their fluid mosaic nature; however, their bending into different shapes is an active process regulated by specific lipids and proteins. The membrane bending can be transient as seen in vesicles or stable for a long time as in microvilli. Cells regulate the size, location, and duration of the membrane curvature.
Membrane bending can happen due to intrinsic changes in lipid composition or extrinsic association with different proteins. The proteins involved...
3.7K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.4K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.4K
Overview of Skeletal Muscle01:15

Overview of Skeletal Muscle

17.2K
Skeletal muscles are composed of a bundle of muscle fibers and are attached to bones through tendons. Each skeletal muscle fiber is a single muscle cell. The sarcolemma, the plasma membrane of a skeletal muscle cell, consists of a lipid bilayer and glycocalyx that supports muscle fibers. The sarcolemma extends into the muscle cells to form tubular structures called transverse or T-tubules. Each side of the T-tubules consists of a membrane-bound structure called the sarcoplasmic reticulum,...
17.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same author

Generation of isogenic rescue iPSC lines by targeted CTG-repeat excision for myotonic dystrophy type 1.

Stem cell research·2026
Same author

Congenital myopathies in adult patients: lived experiences and coping mechanisms.

Disability and rehabilitation·2026
Same author

Generation of iPSC lines from myotonic dystrophy type 1 patients with varying CTG repeat lengths.

Stem cell research·2026
Same author

Commitment to Myogenic Differentiation Significantly Aggravates the RNA Phenotype in Myotonic Dystrophy Type 1.

Neuropathology and applied neurobiology·2026
Same author

Expanding repeats, expanding impact: Somatic instability in myotonic dystrophy type 1.

Journal of neuromuscular diseases·2026

Related Experiment Video

Updated: Apr 15, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.1K

Cell membrane integrity in myotonic dystrophy type 1: implications for therapy.

Anchel González-Barriga1, Julia Kranzen2, Huib J E Croes2

  • 1Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands; Prosensa Therapeutics B.V., Leiden, The Netherlands.

Plos One
|March 24, 2015
PubMed
Summary

Myotonic Dystrophy type 1 (DM1) cells do not show compromised membrane integrity, challenging drug delivery strategies. This finding indicates the cell membrane remains a significant barrier for effective DM1 therapies.

More Related Videos

DNA Electroporation, Isolation and Imaging of Myofibers
07:52

DNA Electroporation, Isolation and Imaging of Myofibers

Published on: December 23, 2015

13.1K
Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.1K
DNA Electroporation, Isolation and Imaging of Myofibers
07:52

DNA Electroporation, Isolation and Imaging of Myofibers

Published on: December 23, 2015

13.1K
Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

9.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Myotonic Dystrophy type 1 (DM1) is a genetic disorder caused by expanded CTG•CAG repeats in the DMPK gene.
  • Current therapeutic strategies for DM1 focus on eliminating toxic RNA or preventing its aberrant interactions.
  • Efficient delivery of therapeutic compounds across cell membranes is a critical challenge for DM1 treatment.

Purpose of the Study:

  • To investigate cell membrane integrity in DM1 mouse models and patient samples.
  • To determine if compromised membrane integrity impacts drug delivery in DM1.
  • To assess sarcolemmal integrity and related markers in DM1.

Main Methods:

  • Assessment of Evans Blue Dye permeability in skeletal muscle, heart, and brain tissues of DM1 mouse models.
  • Measurement of serum creatine kinase levels in DM1 mice.
  • Analysis of dystrophin protein expression and cell surface localization in DM1 patient muscle biopsies.
  • Evaluation of calcium-positive fibers in patient muscle biopsies.

Main Results:

  • Skeletal muscle, heart, and brain membranes in DM1 mice were impermeable to Evans Blue Dye.
  • Serum creatine kinase levels and dystrophin protein expression were unaffected in DM1 mice compared to wild-type.
  • Cell surface dystrophin expression was normal in DM1 patient muscle biopsies, with rare instances of elevated intracellular calcium.

Conclusions:

  • DM1 tissues do not exhibit compromised cell membrane integrity.
  • The cell membrane presents a significant barrier that must be addressed for effective systemic drug delivery in DM1 therapy.
  • These findings necessitate the development of strategies to overcome the cell membrane barrier for future DM1 therapeutics.